ID   TBC23_HUMAN             Reviewed;         699 AA.
AC   Q9NUY8; B9A6M5; Q8TCN8; Q8WUB7; Q96D90; Q9NV75;
DT   15-MAY-2007, integrated into UniProtKB/Swiss-Prot.
DT   13-JUL-2010, sequence version 3.
DT   28-JUN-2023, entry version 160.
DE   RecName: Full=TBC1 domain family member 23;
DE   AltName: Full=HCV non-structural protein 4A-transactivated protein 1;
GN   Name=TBC1D23; Synonyms=NS4ATP1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=Brain;
RX   PubMed=19077034; DOI=10.1111/j.1365-2443.2008.01251.x;
RA   Ishibashi K., Kanno E., Itoh T., Fukuda M.;
RT   "Identification and characterization of a novel Tre-2/Bub2/Cdc16 (TBC)
RT   protein that possesses Rab3A-GAP activity.";
RL   Genes Cells 14:41-52(2009).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16641997; DOI=10.1038/nature04728;
RA   Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R., Buhay C.J.,
RA   Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R., Gunaratne P.,
RA   Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V., Hume J., Jackson A.,
RA   Khan Z.M., Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L.,
RA   Milosavljevic A., Miner G.R., Morgan M.B., Nazareth L.V., Scott G.,
RA   Sodergren E., Song X.-Z., Steffen D., Wei S., Wheeler D.A., Wright M.W.,
RA   Worley K.C., Yuan Y., Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M.,
RA   Brown M.J., Chen G., Chen Z., Clendenning J., Clerc-Blankenburg K.P.,
RA   Chen R., Chen Z., Davis C., Delgado O., Dinh H.H., Dong W., Draper H.,
RA   Ernst S., Fu G., Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J.,
RA   Hao B., Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W.,
RA   Jackson L.R., Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B.,
RA   Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O.,
RA   Palmeiri A., Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B.,
RA   Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H.,
RA   Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J.,
RA   Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J., Zhang X.,
RA   Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H., Reinhardt R.,
RA   Naylor S.L., Yang H., Olson M., Weinstock G., Gibbs R.A.;
RT   "The DNA sequence, annotation and analysis of human chromosome 3.";
RL   Nature 440:1194-1198(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 3-684 (ISOFORM 1), AND NUCLEOTIDE
RP   SEQUENCE [LARGE SCALE MRNA] OF 353-684 (ISOFORM 2).
RC   TISSUE=Colon, and Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 307-684 (ISOFORM 1).
RC   TISSUE=Lymph node;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 365-684 (ISOFORM 1).
RA   Liu Y., Cheng J., Ji D., Yan F., Gao X., Zhang L., Chen J.;
RT   "Homo sapiens gene 1 transactivated by nonstructural protein 4A of
RT   hepatitis C virus (NS4ATP1) mRNA.";
RL   Submitted (SEP-2004) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-474 AND THR-514, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein phosphorylation
RT   analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-507 AND THR-514, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-300; SER-474; SER-507 AND
RP   SER-520, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-571, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [14]
RP   INVOLVEMENT IN PCH11, AND FUNCTION.
RX   PubMed=28823707; DOI=10.1016/j.ajhg.2017.07.010;
RA   Ivanova E.L., Mau-Them F.T., Riazuddin S., Kahrizi K., Laugel V.,
RA   Schaefer E., de Saint Martin A., Runge K., Iqbal Z., Spitz M.A., Laura M.,
RA   Drouot N., Gerard B., Deleuze J.F., de Brouwer A.P.M., Razzaq A.,
RA   Dollfus H., Assir M.Z., Nitchke P., Hinckelmann M.V., Ropers H.,
RA   Riazuddin S., Najmabadi H., van Bokhoven H., Chelly J.;
RT   "Homozygous truncating variants in TBC1D23 cause pontocerebellar hypoplasia
RT   and alter cortical development.";
RL   Am. J. Hum. Genet. 101:428-440(2017).
RN   [15]
RP   INVOLVEMENT IN PCH11, VARIANT PCH11 GLN-518, SUBCELLULAR LOCATION, AND
RP   TISSUE SPECIFICITY.
RX   PubMed=28823706; DOI=10.1016/j.ajhg.2017.07.015;
RA   Marin-Valencia I., Gerondopoulos A., Zaki M.S., Ben-Omran T.,
RA   Almureikhi M., Demir E., Guemez-Gamboa A., Gregor A., Issa M.Y.,
RA   Appelhof B., Roosing S., Musaev D., Rosti B., Wirth S., Stanley V.,
RA   Baas F., Barr F.A., Gleeson J.G.;
RT   "Homozygous mutations in TBC1D23 lead to a non-degenerative form of
RT   pontocerebellar hypoplasia.";
RL   Am. J. Hum. Genet. 101:441-450(2017).
RN   [16]
RP   FUNCTION, INTERACTION WITH C17ORF75; FAM91A1; FKBP15; GOLGA1; GOLGA4;
RP   WASHC1; WASHC2A AND WDR11, AND SUBCELLULAR LOCATION.
RX   PubMed=29084197; DOI=10.1038/ncb3627;
RA   Shin J.J.H., Gillingham A.K., Begum F., Chadwick J., Munro S.;
RT   "TBC1D23 is a bridging factor for endosomal vesicle capture by golgins at
RT   the trans-Golgi.";
RL   Nat. Cell Biol. 19:1424-1432(2017).
RN   [17]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH THE COMPLEX WDR11.
RX   PubMed=29426865; DOI=10.1038/s41467-018-02919-4;
RA   Navarro Negredo P., Edgar J.R., Manna P.T., Antrobus R., Robinson M.S.;
RT   "The WDR11 complex facilitates the tethering of AP-1-derived vesicles.";
RL   Nat. Commun. 9:596-596(2018).
CC   -!- FUNCTION: Putative Rab GTPase-activating protein which plays a role in
CC       vesicular trafficking (PubMed:28823707). Involved in endosome-to-Golgi
CC       trafficking. Acts as a bridging protein by binding simultaneously to
CC       golgins, including GOLGA1 and GOLGA4, located at the trans-Golgi, and
CC       to the WASH complex, located on endosome-derived vesicles
CC       (PubMed:29084197, PubMed:29426865). Together with WDR11 complex
CC       facilitates the golgin-mediated capture of vesicles generated using AP-
CC       1 (PubMed:29426865). Plays a role in brain development, including in
CC       cortical neuron positioning (By similarity). May also be important for
CC       neurite outgrowth, possibly through its involvement in membrane
CC       trafficking and cargo delivery, 2 processes that are essential for
CC       axonal and dendritic growth (By similarity). May act as a general
CC       inhibitor of innate immunity signaling, strongly inhibiting multiple
CC       TLR and dectin/CLEC7A-signaling pathways. Does not alter initial
CC       activation events, but instead affects maintenance of inflammatory gene
CC       expression several hours after bacterial lipopolysaccharide (LPS)
CC       challenge (By similarity). {ECO:0000250|UniProtKB:Q8K0F1,
CC       ECO:0000269|PubMed:28823707, ECO:0000269|PubMed:29084197,
CC       ECO:0000269|PubMed:29426865}.
CC   -!- SUBUNIT: Directly interacts with GOLGA1 and GOLGA4 (PubMed:29084197).
CC       Interacts with FAM91A1, C17ORF75 and WDR11; the interaction recruits
CC       TBC1D23 to AP-1-derived vesicles (PubMed:29084197, PubMed:29426865).
CC       Directly interacts with WASHC1 and WASHC2A/FAM21A (PubMed:29084197).
CC       Interacts with FKBP15 (PubMed:29084197). {ECO:0000269|PubMed:29084197,
CC       ECO:0000269|PubMed:29426865}.
CC   -!- INTERACTION:
CC       Q9NUY8; Q8TC20: CAGE1; NbExp=3; IntAct=EBI-2853126, EBI-10196469;
CC       Q9NUY8; Q7L5A3: FAM214B; NbExp=3; IntAct=EBI-2853126, EBI-745689;
CC       Q9NUY8; P60410: KRTAP10-8; NbExp=3; IntAct=EBI-2853126, EBI-10171774;
CC       Q9NUY8; P60411: KRTAP10-9; NbExp=3; IntAct=EBI-2853126, EBI-10172052;
CC       Q9NUY8; Q9BQ66: KRTAP4-12; NbExp=3; IntAct=EBI-2853126, EBI-739863;
CC       Q9NUY8; Q9BWW4: SSBP3; NbExp=3; IntAct=EBI-2853126, EBI-2902395;
CC       Q9NUY8; O43379: WDR62; NbExp=3; IntAct=EBI-2853126, EBI-714790;
CC       Q9NUY8-2; Q8TC20: CAGE1; NbExp=3; IntAct=EBI-10314276, EBI-10196469;
CC       Q9NUY8-2; P60411: KRTAP10-9; NbExp=3; IntAct=EBI-10314276, EBI-10172052;
CC       Q9NUY8-2; Q7Z699: SPRED1; NbExp=3; IntAct=EBI-10314276, EBI-5235340;
CC       Q9NUY8-2; Q9BWW4: SSBP3; NbExp=3; IntAct=EBI-10314276, EBI-2902395;
CC       Q9NUY8-2; O43379: WDR62; NbExp=3; IntAct=EBI-10314276, EBI-714790;
CC   -!- SUBCELLULAR LOCATION: Golgi apparatus, trans-Golgi network
CC       {ECO:0000269|PubMed:28823706, ECO:0000269|PubMed:29084197,
CC       ECO:0000269|PubMed:29426865}. Cytoplasmic vesicle
CC       {ECO:0000269|PubMed:29426865}. Note=Localization to the trans-Golgi is
CC       regulated by ARL1 and ARL5B/ARL8. ARL1 increases Golgi localization,
CC       while ARL5B decreases it. Recruitment to the trans-Golgi network
CC       requires the presence of GOLGA1 and GOLGA4, but not that of FAM91A1
CC       (PubMed:29084197, PubMed:28823706). Recruited on AP-1-derived vesicles
CC       by WDR11 complex (PubMed:29426865). {ECO:0000269|PubMed:28823706,
CC       ECO:0000269|PubMed:29084197, ECO:0000269|PubMed:29426865}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9NUY8-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9NUY8-2; Sequence=VSP_025519;
CC   -!- TISSUE SPECIFICITY: Isoform 1: Widely expressed, including in fetal
CC       adult brain (corpus callosum, pons, cerebellum), spinal cord, heart,
CC       skeletal muscle, thymus and bone marrow, and at lower levels in spleen.
CC       Hardly detected in liver, kidney, colon and testis. Isoform 2:
CC       Expressed at high levels in liver, kidney, colon and testis. Hardly
CC       detected in tissues expressing high levels of isoform 1. Expressed at
CC       low levels in spleen. {ECO:0000269|PubMed:28823706}.
CC   -!- DISEASE: Pontocerebellar hypoplasia 11 (PCH11) [MIM:617695]: A non-
CC       degenerative form of pontocerebellar hypoplasia, a disorder
CC       characterized by structural defects of the pons and cerebellum, evident
CC       upon brain imaging. PCH11 features include severely delayed psychomotor
CC       development with intellectual disability and poor speech, microcephaly,
CC       dysmorphic features, and pontocerebellar hypoplasia. PCH11 inheritance
CC       is autosomal recessive. {ECO:0000269|PubMed:28823706,
CC       ECO:0000269|PubMed:28823707}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH10221.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=AAH20955.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=BAA91881.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB449910; BAH16653.1; -; mRNA.
DR   EMBL; AK001750; BAA91881.1; ALT_INIT; mRNA.
DR   EMBL; AK001908; BAA91973.1; -; mRNA.
DR   EMBL; AC078783; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC093003; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC010221; AAH10221.1; ALT_INIT; mRNA.
DR   EMBL; BC020955; AAH20955.1; ALT_INIT; mRNA.
DR   EMBL; AL713684; CAD28488.1; -; mRNA.
DR   EMBL; AY740521; AAW66944.1; -; mRNA.
DR   CCDS; CCDS2936.1; -. [Q9NUY8-2]
DR   CCDS; CCDS56265.1; -. [Q9NUY8-1]
DR   RefSeq; NP_001186127.1; NM_001199198.2. [Q9NUY8-1]
DR   RefSeq; NP_060779.2; NM_018309.4. [Q9NUY8-2]
DR   PDB; 6JL7; X-ray; 2.50 A; A=17-460.
DR   PDB; 6JM5; X-ray; 1.60 A; A/B=577-699.
DR   PDBsum; 6JL7; -.
DR   PDBsum; 6JM5; -.
DR   AlphaFoldDB; Q9NUY8; -.
DR   SMR; Q9NUY8; -.
DR   BioGRID; 120889; 54.
DR   IntAct; Q9NUY8; 22.
DR   MINT; Q9NUY8; -.
DR   STRING; 9606.ENSP00000377700; -.
DR   iPTMnet; Q9NUY8; -.
DR   PhosphoSitePlus; Q9NUY8; -.
DR   BioMuta; TBC1D23; -.
DR   DMDM; 300669675; -.
DR   EPD; Q9NUY8; -.
DR   jPOST; Q9NUY8; -.
DR   MassIVE; Q9NUY8; -.
DR   MaxQB; Q9NUY8; -.
DR   PaxDb; Q9NUY8; -.
DR   PeptideAtlas; Q9NUY8; -.
DR   ProteomicsDB; 82728; -. [Q9NUY8-1]
DR   ProteomicsDB; 82729; -. [Q9NUY8-2]
DR   Antibodypedia; 46507; 78 antibodies from 22 providers.
DR   DNASU; 55773; -.
DR   Ensembl; ENST00000344949.9; ENSP00000340693.5; ENSG00000036054.13. [Q9NUY8-2]
DR   Ensembl; ENST00000394144.9; ENSP00000377700.4; ENSG00000036054.13. [Q9NUY8-1]
DR   GeneID; 55773; -.
DR   KEGG; hsa:55773; -.
DR   MANE-Select; ENST00000394144.9; ENSP00000377700.4; NM_001199198.3; NP_001186127.1.
DR   UCSC; uc003dts.5; human. [Q9NUY8-1]
DR   AGR; HGNC:25622; -.
DR   CTD; 55773; -.
DR   DisGeNET; 55773; -.
DR   GeneCards; TBC1D23; -.
DR   HGNC; HGNC:25622; TBC1D23.
DR   HPA; ENSG00000036054; Low tissue specificity.
DR   MalaCards; TBC1D23; -.
DR   MIM; 617687; gene.
DR   MIM; 617695; phenotype.
DR   neXtProt; NX_Q9NUY8; -.
DR   OpenTargets; ENSG00000036054; -.
DR   PharmGKB; PA142670829; -.
DR   VEuPathDB; HostDB:ENSG00000036054; -.
DR   eggNOG; KOG3636; Eukaryota.
DR   GeneTree; ENSGT00390000000191; -.
DR   HOGENOM; CLU_026555_0_0_1; -.
DR   InParanoid; Q9NUY8; -.
DR   OMA; NDIYSIC; -.
DR   OrthoDB; 91822at2759; -.
DR   PhylomeDB; Q9NUY8; -.
DR   TreeFam; TF105892; -.
DR   PathwayCommons; Q9NUY8; -.
DR   SignaLink; Q9NUY8; -.
DR   BioGRID-ORCS; 55773; 18 hits in 1156 CRISPR screens.
DR   ChiTaRS; TBC1D23; human.
DR   GenomeRNAi; 55773; -.
DR   Pharos; Q9NUY8; Tbio.
DR   PRO; PR:Q9NUY8; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   RNAct; Q9NUY8; protein.
DR   Bgee; ENSG00000036054; Expressed in cardiac muscle of right atrium and 188 other tissues.
DR   ExpressionAtlas; Q9NUY8; baseline and differential.
DR   Genevisible; Q9NUY8; HS.
DR   GO; GO:0031410; C:cytoplasmic vesicle; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IEA:GOC.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:HPA.
DR   GO; GO:0005802; C:trans-Golgi network; IDA:UniProtKB.
DR   GO; GO:0007420; P:brain development; IMP:UniProtKB.
DR   GO; GO:1990403; P:embryonic brain development; ISS:UniProtKB.
DR   GO; GO:0031175; P:neuron projection development; ISS:UniProtKB.
DR   GO; GO:0042147; P:retrograde transport, endosome to Golgi; IMP:UniProtKB.
DR   GO; GO:0099041; P:vesicle tethering to Golgi; IDA:UniProtKB.
DR   GO; GO:0016192; P:vesicle-mediated transport; ISS:UniProtKB.
DR   CDD; cd20788; TBC1D23_C-like; 1.
DR   Gene3D; 3.40.250.10; Rhodanese-like domain; 1.
DR   Gene3D; 1.10.472.80; Ypt/Rab-GAP domain of gyp1p, domain 3; 1.
DR   InterPro; IPR000195; Rab-GAP-TBC_dom.
DR   InterPro; IPR035969; Rab-GAP_TBC_sf.
DR   InterPro; IPR001763; Rhodanese-like_dom.
DR   InterPro; IPR036873; Rhodanese-like_dom_sf.
DR   InterPro; IPR039755; TBC1D23.
DR   InterPro; IPR045799; TBC1D23_C.
DR   PANTHER; PTHR13297:SF5; TBC1 DOMAIN FAMILY MEMBER 23; 1.
DR   PANTHER; PTHR13297; UNCHARACTERIZED; 1.
DR   Pfam; PF00566; RabGAP-TBC; 1.
DR   Pfam; PF00581; Rhodanese; 1.
DR   Pfam; PF19430; TBC1D23_C; 1.
DR   SMART; SM00164; TBC; 1.
DR   SUPFAM; SSF52821; Rhodanese/Cell cycle control phosphatase; 1.
DR   SUPFAM; SSF47923; Ypt/Rab-GAP domain of gyp1p; 2.
DR   PROSITE; PS50206; RHODANESE_3; 1.
DR   PROSITE; PS50086; TBC_RABGAP; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cytoplasmic vesicle;
KW   Developmental protein; Disease variant; Golgi apparatus; Phosphoprotein;
KW   Reference proteome.
FT   CHAIN           1..699
FT                   /note="TBC1 domain family member 23"
FT                   /id="PRO_0000287497"
FT   DOMAIN          44..225
FT                   /note="Rab-GAP TBC"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00163"
FT   DOMAIN          334..446
FT                   /note="Rhodanese"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00173"
FT   REGION          459..483
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          514..699
FT                   /note="May mediate the interaction with WASHC1"
FT                   /evidence="ECO:0000250|UniProtKB:Q8K0F1"
FT   REGION          514..573
FT                   /note="May mediate the interaction with C17orf75, FAM91A1
FT                   and WDR11"
FT                   /evidence="ECO:0000250|UniProtKB:Q8K0F1"
FT   REGION          574..699
FT                   /note="May mediate the interaction with FKBP15 and WASHC2;
FT                   required for endosome to Golgi trafficking"
FT                   /evidence="ECO:0000250|UniProtKB:Q8K0F1"
FT   MOD_RES         300
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         469
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8K0F1"
FT   MOD_RES         474
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:16964243,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         507
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         514
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:16964243,
FT                   ECO:0007744|PubMed:18669648"
FT   MOD_RES         520
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         571
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   VAR_SEQ         518..532
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:19077034"
FT                   /id="VSP_025519"
FT   VARIANT         518
FT                   /note="R -> Q (in PCH11; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:28823706"
FT                   /id="VAR_080040"
FT   CONFLICT        66
FT                   /note="S -> C (in Ref. 1; BAH16653 and 2; BAA91973)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        170
FT                   /note="L -> P (in Ref. 1; BAH16653 and 2; BAA91973)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        360
FT                   /note="L -> S (in Ref. 2; BAA91973)"
FT                   /evidence="ECO:0000305"
FT   HELIX           18..27
FT                   /evidence="ECO:0007829|PDB:6JL7"
FT   HELIX           33..40
FT                   /evidence="ECO:0007829|PDB:6JL7"
FT   TURN            47..49
FT                   /evidence="ECO:0007829|PDB:6JL7"
FT   HELIX           50..57
FT                   /evidence="ECO:0007829|PDB:6JL7"
FT   HELIX           67..70
FT                   /evidence="ECO:0007829|PDB:6JL7"
FT   HELIX           79..93
FT                   /evidence="ECO:0007829|PDB:6JL7"
FT   HELIX           100..117
FT                   /evidence="ECO:0007829|PDB:6JL7"
FT   HELIX           128..138
FT                   /evidence="ECO:0007829|PDB:6JL7"
FT   HELIX           142..155
FT                   /evidence="ECO:0007829|PDB:6JL7"
FT   HELIX           159..161
FT                   /evidence="ECO:0007829|PDB:6JL7"
FT   TURN            162..164
FT                   /evidence="ECO:0007829|PDB:6JL7"
FT   HELIX           166..178
FT                   /evidence="ECO:0007829|PDB:6JL7"
FT   HELIX           180..188
FT                   /evidence="ECO:0007829|PDB:6JL7"
FT   HELIX           193..203
FT                   /evidence="ECO:0007829|PDB:6JL7"
FT   TURN            204..208
FT                   /evidence="ECO:0007829|PDB:6JL7"
FT   HELIX           211..224
FT                   /evidence="ECO:0007829|PDB:6JL7"
FT   HELIX           229..240
FT                   /evidence="ECO:0007829|PDB:6JL7"
FT   HELIX           242..247
FT                   /evidence="ECO:0007829|PDB:6JL7"
FT   HELIX           253..261
FT                   /evidence="ECO:0007829|PDB:6JL7"
FT   HELIX           264..266
FT                   /evidence="ECO:0007829|PDB:6JL7"
FT   HELIX           269..271
FT                   /evidence="ECO:0007829|PDB:6JL7"
FT   HELIX           272..284
FT                   /evidence="ECO:0007829|PDB:6JL7"
FT   HELIX           289..292
FT                   /evidence="ECO:0007829|PDB:6JL7"
FT   HELIX           295..297
FT                   /evidence="ECO:0007829|PDB:6JL7"
FT   STRAND          305..307
FT                   /evidence="ECO:0007829|PDB:6JL7"
FT   STRAND          312..314
FT                   /evidence="ECO:0007829|PDB:6JL7"
FT   STRAND          316..320
FT                   /evidence="ECO:0007829|PDB:6JL7"
FT   HELIX           322..331
FT                   /evidence="ECO:0007829|PDB:6JL7"
FT   STRAND          333..335
FT                   /evidence="ECO:0007829|PDB:6JL7"
FT   STRAND          338..342
FT                   /evidence="ECO:0007829|PDB:6JL7"
FT   HELIX           346..351
FT                   /evidence="ECO:0007829|PDB:6JL7"
FT   STRAND          352..354
FT                   /evidence="ECO:0007829|PDB:6JL7"
FT   HELIX           364..367
FT                   /evidence="ECO:0007829|PDB:6JL7"
FT   HELIX           369..389
FT                   /evidence="ECO:0007829|PDB:6JL7"
FT   STRAND          396..401
FT                   /evidence="ECO:0007829|PDB:6JL7"
FT   TURN            406..410
FT                   /evidence="ECO:0007829|PDB:6JL7"
FT   HELIX           411..421
FT                   /evidence="ECO:0007829|PDB:6JL7"
FT   STRAND          425..430
FT                   /evidence="ECO:0007829|PDB:6JL7"
FT   HELIX           433..444
FT                   /evidence="ECO:0007829|PDB:6JL7"
FT   STRAND          450..454
FT                   /evidence="ECO:0007829|PDB:6JL7"
FT   STRAND          456..458
FT                   /evidence="ECO:0007829|PDB:6JL7"
FT   STRAND          578..580
FT                   /evidence="ECO:0007829|PDB:6JM5"
FT   HELIX           581..585
FT                   /evidence="ECO:0007829|PDB:6JM5"
FT   STRAND          592..599
FT                   /evidence="ECO:0007829|PDB:6JM5"
FT   STRAND          601..603
FT                   /evidence="ECO:0007829|PDB:6JM5"
FT   STRAND          605..612
FT                   /evidence="ECO:0007829|PDB:6JM5"
FT   STRAND          614..622
FT                   /evidence="ECO:0007829|PDB:6JM5"
FT   STRAND          629..637
FT                   /evidence="ECO:0007829|PDB:6JM5"
FT   HELIX           638..640
FT                   /evidence="ECO:0007829|PDB:6JM5"
FT   STRAND          641..647
FT                   /evidence="ECO:0007829|PDB:6JM5"
FT   STRAND          650..662
FT                   /evidence="ECO:0007829|PDB:6JM5"
FT   STRAND          665..675
FT                   /evidence="ECO:0007829|PDB:6JM5"
FT   HELIX           679..694
FT                   /evidence="ECO:0007829|PDB:6JM5"
SQ   SEQUENCE   699 AA;  78322 MW;  C0AEB80E044B0F98 CRC64;
     MAEGEDVPPL PTSSGDGWEK DLEEALEAGG CDLETLRNII QGRPLPADLR AKVWKIALNV
     AGKGDSLASW DGILDLPEQN TIHKDCLQFI DQLSVPEEKA AELLLDIESV ITFYCKSRNI
     KYSTSLSWIH LLKPLVHLQL PRSDLYNCFY AIMNKYIPRD CSQKGRPFHL FRLLIQYHEP
     ELCSYLDTKK ITPDSYALNW LGSLFACYCS TEVTQAIWDG YLQQADPFFI YFLMLIILVN
     AKEVILTQES DSKEEVIKFL ENTPSSLNIE DIEDLFSLAQ YYCSKTPASF RKDNHHLFGS
     TLLGIKDDDA DLSQALCLAI SVSEILQANQ LQGEGVRFFV VDCRPAEQYN AGHLSTAFHL
     DSDLMLQNPS EFAQSVKSLL EAQKQSIESG SIAGGEHLCF MGSGREEEDM YMNMVLAHFL
     QKNKEYVSIA SGGFMALQQH LADINVDGPE NGYGHWIAST SGSRSSINSV DGESPNGSSD
     RGMKSLVNKM TVALKTKSVN VREKVISFIE NTSTPVDRMS FNLPWPDRSC TERHVSSSDR
     VGKPYRGVKP VFSIGDEEEY DTDEIDSSSM SDDDRKEVVN IQTWINKPDV KHHFPCKEVK
     ESGHMFPSHL LVTATHMYCL REIVSRKGLA YIQSRQALNS VVKITSKKKH PELITFKYGN
     SSASGIEILA IERYLIPNAG DATKAIKQQI MKVLDALES
//
